The Efficacy and Safety of Adjuvant GLP-1 Receptor Agonist Therapy Following Metabolic Bariatric Surgery in Chinese Patients With Obesity: A Prospective, Monocentric, Stratified Randomized Controlled Trial
Status: Recruiting
Location: See location...
Intervention Type: Combination product, Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with monotherapy. While bariatric surgery remains the most effective weight-loss intervention, postoperative weight regain and metabolic deterioration remain significant concerns. glucagon-like peptide-1 receptor agonists (GLP-1RA) offer distinct advantages for weight loss and metabolic control, and their combination with surgery may produce synergistic effects. This study investigates the efficacy and safety of bariatric surgery combined with adjuvant GLP-1 receptor agonist therapy for Chinese patients with obesity.
• Metabolic comorbidities: Diagnosis of metabolic syndrome or type 2 diabetes mellitus (T2DM) meeting standard criteria.
• Age range: 18-60 years (inclusive).
• Informed consent: Willing participation with documented consent.
Locations
Other Locations
China
China-Japan Friendship Hospital
RECRUITING
Beijing
Contact Information
Primary
Yishan Huang, Ph.D
yuanwen0920@163.com
+8618612256920
Time Frame
Start Date:2026-05-01
Estimated Completion Date:2028-05-01
Participants
Target number of participants:200
Treatments
Experimental: LSG-Semaglutide group
Names for Surgery: Laparoscopic Sleeve Gastrectomy. Names for drugs: Semaglutide. Dosage:The starting dose was 0.25 mg per week and was subsequently titrated up based on individual patient response to a maximum maintenance dose of 2.4 mg per week.~Frequency: Once per week. Duration: The treatment continued until the completion of the 6-month postoperative period.
Experimental: LSG-Mazdutide group
Names for Surgery: Laparoscopic Sleeve Gastrectomy. Names for drugs:Mazdutide. Dosage:The starting dose was 2 mg per week and was subsequently titrated up based on individual patient response to a maximum maintenance dose of 6 mg per week.~Frequency: Once per week. Duration: The treatment continued until the completion of the 6-month postoperative period.
Experimental: LSG-Tirzepatide group
Names for Surgery: Laparoscopic Sleeve Gastrectomy. Names for drugs:Tirzepatide. Dosage:The starting dose was 2.5 mg per week and was subsequently titrated up based on individual patient response to a maximum maintenance dose of 10 mg per week.~Frequency: Once per week. Duration: The treatment continued until the completion of the 6-month postoperative period.
Other: LSG group
Names for Surgery: Laparoscopic Sleeve Gastrectomy. Names for drugs: N/A. Observation Group: Received only basic nutritional recommendation interventions after surgery.